CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of its previously announced public offering of 24,725,000 shares of common stock, including 3,225,000 shares issued pursuant to the underwriters’ exercise of their over-allotment option, at a public offering price of $10.42 per share, for total gross proceeds of approximately $258 million. Net proceeds to ARIAD from the offering are approximately $243 million after deducting underwriting discounts and commissions and estimated offering expenses.
